← All trials
NCT04055454
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2019
- Primary completion
- Apr 30, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Themis Bioscience GmbHLead sponsor
- Assign Clinical Research GmbHCollaborator
- Coalition for Epidemic Preparedness InnovationsCollaborator
- University of AntwerpOverall official - principal investigator
- Harmony Clinical ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.